Results 211 to 220 of about 220,119 (313)

High Levels of Viral Replication during Primary Simian Immunodeficiency Virus SIVagm Infection Are Rapidly and Strongly Controlled in African Green Monkeys [PDF]

, 2000
Ousmane M. Diop, Aïssatou Guèye, Marisa Dias-Tavares, C.G. Kornfeld, Abdourahmane Faye, Patrick Avé, Michel Huerre, Sylvie Corbet, Françoise Barré‐Sinoussi, Michaela Müller‐Trutwin   +9 more
openalex   +1 more source

Lipid metabolism reprograming by SREBP1‐PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy

Cancer Communications, EarlyView.
Abstract Background Pancreatic cancer's aberrant lipid metabolism fuels cell growth, invasion, and metastasis, yet its impact on immune surveillance and immunotherapy is unclear. This study investigated how sterol regulatory element‐binding transcription factor 1 (SREBP1)‐driven lipid metabolism affects the tumor microenvironment (TME) in pancreatic ...
Mengyi Lao, Xiaozhen Zhang, Zejun Li, Kang Sun, Hanshen Yang, Sicheng Wang, Lihong He, Yan Chen, Hanjia Zhang, Jiatao Shi, Daqian Xu, Tingbo Liang, Xueli Bai   +12 more
wiley   +1 more source

Corrigendum to “Immune defects in active mycobacterial diseases in patients with primary immunodeficiency diseases (PIDs)”

Journal of the Formosan Medical Association, 2012
Wen-I. Lee, Jing-Long Huang, Kuo-Wei Yeh, Tang-Her Jaing, Tzou-Yien Lin, Yhu-Chering Huang, Cheng-Hsun Chiu   +6 more
doaj   +1 more source

Efficacy, Safety, Tolerability, and Serum IgG Trough Levels of Hyaluronidase-Facilitated Subcutaneous Immunoglobulin 10% in US Pediatric Patients with Primary Immunodeficiency Diseases. [PDF]

J Clin Immunol
Patel NC, Walter JE, Wasserman RL, Rubinstein A, Kankirawatana S, Shepherd MW, Greco E, Li Z, Russo-Schwarzbaum S, Saeed-Khawaja S, McCoy B, Yel L.   +11 more
europepmc   +1 more source

Minimal Incidence of Serum Antibodies Reactive with Intact Primary Isolate Virions in Human Immunodeficiency Virus Type 1-Infected Individuals

, 1999
Lisa A. Cavacini, Jennifer E. Peterson, Erica Nappi, Mark Duval, Robert H. Goldstein, Kenneth H. Mayer, Marshall R. Posner   +6 more
openalex   +1 more source

Tislelizumab: Structural Innovations and Expanding Clinical Horizons in Next‐Generation PD‐1 Immunotherapy

Chronic Diseases and Translational Medicine, EarlyView.
The interaction of tislelizumab with PD‐1/PD‐L1 in the tumor microenvironment. Tislelizumab targets PD‐1 on T cells, blocking its interaction with PD‐L1 on tumor cells. This action is facilitated by a modified F(ab) region that limits Fc‐γ receptor binding, thereby enhancing the antitumor immune response. ABSTRACT Tislelizumab is a next‐generation PD‐1
Thy T. Nguyen, Bohan Zhang, Luke Zhong, Xiuyi Liang, Letao Bo   +4 more
wiley   +1 more source

fSCIG 10% in pediatric primary immunodeficiency diseases: a European post-authorization safety study. [PDF]

Allergy Asthma Clin Immunol
Čižnár P, Roderick M, Schneiderova H, Jeseňák M, Kriván G, Brodszki N, Jolles S, Atisso C, Fielhauer K, Saeed-Khawaja S, McCoy B, Yel L.   +11 more
europepmc   +1 more source

Comparison of Serum and Plasma Viral RNA Measurements in Primary and Chronic Human Immunodeficiency Virus Type 1 Infection

, 1997
Ray J. Rodriguez, Deborah E. Dayhoff, George J. Chang, Sharon Cassol, Deborah L. Birx, Andrew W. Artenstein, N L Michael   +6 more
openalex   +1 more source

Harnessing Viral Proteases for Cellular and Molecular Engineering

Chemistry–Methods, EarlyView.
Engineered viral proteases (VIPs) provide programmable control of protein function with high specificity and low toxicity. Integrated with chemogenetic and optogenetic modules, these VIP systems enable logic gate manipulation for targeted regulation of cell signaling, gene expression, protein secretion, and degradation, thereby offering versatile ...
Mingguang Cui, Tien‐Hung Lan, Yubin Zhou   +2 more
wiley   +1 more source

Lymphoproliferation, Autoimmunity, and Recurrent Infections: Which Primary Immunodeficiency? [PDF]

Turk Arch Pediatr
Öztürk G, Haskoloğlu Ş, Deveci N, Erkmen H, Çelik NA, Sucak G, Ceylaner S, İkincioğulları A, Doğu F.   +8 more
europepmc   +1 more source